Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
Pharma
Vaccines
Asia
Cell & Gene Therapy
Drug Delivery
Executives
Manufacturing
Facilities
Recalls
Warning Letters
Marketing
Special Reports
Fierce 50
Special Report
Awards Gala
Trending
Oncology
Supply Chain
Awards
CRO Awards
Innovation Awards
Pharma Marketing Awards
Resources
Podcasts
Fierce Events
Industry Events
Webinars
Whitepapers
Survey
Events
Subscribe
Subscribe
Pharma
Vaccines
Asia
Cell & Gene Therapy
Drug Delivery
Executives
Manufacturing
Facilities
Recalls
Warning Letters
Marketing
Special Reports
Fierce 50
Special Report
Awards Gala
Trending
Oncology
Supply Chain
Awards
CRO Awards
Innovation Awards
Pharma Marketing Awards
Resources
Podcasts
Fierce Events
Industry Events
Webinars
Whitepapers
Survey
Events
Subscribe
Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
follicular lymphoma
Pharma
Roche's bispecific Lunsumio goes subcutaneous
The new under-the-skin formulation reduces the Lunsumio administration time to about one minute compared with two to four hours for an infusion.
Angus Liu
Dec 22, 2025 10:15am
FDA OKs BMS' Breyanzi as first CAR-T for marginal zone lymphoma
Dec 5, 2025 11:00am
Genmab touts new data that set up Epkinly for FL expansion
Aug 8, 2025 7:25am
ASH: Roche's subQ Lunsumio matches IV version in lymphoma
Dec 9, 2024 3:16pm
Incyte's Monjuvi proves its worth in follicular lymphoma
Nov 25, 2024 3:20pm
EU signs off on Regeneron's T-cell engager for 2 blood cancers
Aug 26, 2024 10:35am
